Skip to main content
OpenTrials
Completed

NCT Number: NCT00612274

Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute GVHD in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation

The primary objective of this trial is to study the safety and efficacy of a novel regimen of sirolimus, tacrolimus and methotrexate as prophylaxis against acute graft versus host disease (GVHD) in recipients of mismatched unrelated donor stem cell grafts. Methotrexate is administered in a low dose format of 5mg/m2 on days +1,3 and 6 only.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stem Cell Transplantation

Age range

16 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Yale University School of Medicine

New Haven, Connecticut, 06520, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must have an identified 8/10 or 9/10 matched unrelated donor identified following a formal search with confirmatory typing through the national marrow donor program as the best available donor. No matched sibling or fully matched unrelated donor has been identified. HLA typing of donor and recipient will be performed by high resolution molecular typing at HLA A, B, C and DRB1/DQ loci. Patients whose best available donor is matched at 8/10 loci must have at least one of the mismatches at the DQ locus. (no more than one mismatch at HLA A,B,C,DR allowed).
  • Candidates for this trial will meet the following criteria:
  • Adequate organ function for conditioning type:

For patients receiving ablative conditioning

  • Left Ventricular ejection fraction >45%
  • DLCO >50%
  • Creatinine <1.5
  • Hepatic enzymes <3x upper limit of normal.
  • KPS >70%

For patients receiving non-ablative conditioning:

  • KPS >70%
  • Patients with the following diseases will be considered eligible:
  • AML in first remission with high risk features (poor risk cytogenetic abnormalities9, persistent elevated blast count on day +15 or recovery marrow after induction therapy).
  • AML beyond first remission
  • ALL in first remission with high risk features (ph+, t4:11)
  • ALL beyond first remission
  • High risk Myelodysplasia (RAEB-II, RAEB-I with poor-risk cytogenetics)
  • Recurrent Aggressive Non-Hodgkins or Hodgkins lymphoma (indolent histologies excluded) who have failed autologous transplant or have had inadequate response to salvage therapy.
  • CML with transformation
  • CLL with transformation or Fludarabine failure.
  • Severe aplastic anemia with recurrence or failure after immunosuppressive therapy.

Exclusion criteria

  • Prior allogeneic transplantation
  • Active CNS leukemia.
  • Female patients who are pregnant or breast feeding
  • Karnofsky performance status <70%.
  • Active viral, bacterial or fungal infection.
  • Patients seropositive for HIV -1,2; HTLV -1,2 (due to the additional immunodeficiency induced by transplantation and immunosuppressive therapy) Requirement for antifungal prophylaxis with Voriconazole for the first 30 days is prohibited.
  • Patients not providing informed consent.

Treatment and study plan

Tacrolimus

Drug

Tacrolimus will be administered at a dose of .02mg/kg/d IVCI beginning day -3 until able to take oral medicines reliably. Blood levels will be maintained at 5-10 ng/ml. The oral dose will be 4 times the IV dose. Tacrolimus will be converted to oral dosing prior to hospital discharge. Tacrolimus will be continued until 4 months post transplant (day +120) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.

Other names: FK506, Prograf(TM)

sirolimus

Drug

Sirolimus will be administered as a 12 mg oral loading dose on day -3 followed by 4mg daily. Sirolimus levels will be obtained on day +0 and then at least twice weekly to maintain a trough serum level of 3-12 ng/ml. Sirolimus will be continued until 5 months post transplant (day +150) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.

Other names: Rapamune

methotrexate

Drug

Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.

Primary outcomes

  1. Safety/Efficacy of a novel regimen of sirolimus, tacrolimus and methotrexate

    Time frame: Upon completion of study

Sponsors and collaborators

Lead sponsor

Yale University

Other

Registry information

Official study title

Pilot Study of Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute Graft Versus Host Disease in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation

Important dates

Study start
2007
Primary completion
2014
Study completion
2014
First posted
Feb 11, 2008
Registry last updated
Nov 30, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.